Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
ID: 348274Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348274
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for research that enhances the diagnosis, management, and treatment of rare diseases, promoting collaborative, multi-site, patient-centric, translational, and clinical research. The RDCRC will focus on developing outcome measures that address unmet clinical trial readiness needs, thereby advancing the field of rare disease research. The estimated total program funding is $1,000,000, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare for a cooperative agreement under the U54 activity code, with an anticipated award date of July 1, 2025.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of Clinical Sites for the Undiagnosed Diseases Network (U01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for a Limited Competition aimed at continuing the support for Clinical Sites within the Undiagnosed Diseases Network (UDN). This initiative is specifically designed for institutions and Program Directors/Principal Investigators who have previously received NIH funding under the UDN program, allowing them to compete for an additional year of funding to enhance their participation, establish collaborations, and develop sustainability plans as the network transitions into a national resource. The total estimated program funding is $6.5 million, with an award ceiling of $400,000 and an expected 11 awards to be made. Interested applicants should note that the FOA is anticipated to be published in August 2022, with applications due by September 2022. For further inquiries, potential applicants can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the establishment of Diagnostic Centers of Excellence (DCoE) as part of the Undiagnosed Diseases Network (UDN). The initiative aims to enhance the diagnostic journey for patients with undiagnosed diseases by creating a self-sustained network that provides expert diagnostic services and fosters scientific discovery, with a focus on utilizing genomics data. Eligible applicants will be clinical sites in the U.S. that can demonstrate the necessary infrastructure and expertise to conduct clinical evaluations and DNA sequencing, with the opportunity to enroll a minimum of five participants annually. Interested parties can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373 for further details. The program announcement is expected to be published in spring 2023, with applications due in early summer 2023, and the maximum period of performance for awarded projects will be five years.
    Notice of Intent to Publish a Funding Opportunity Announcement for Intellectual and Developmental Disabilities Research Centers 2025 (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Intellectual and Developmental Disabilities Research Centers (IDDRCs) in 2025, with a focus on advancing research in the diagnosis, prevention, treatment, and amelioration of intellectual and developmental disabilities (IDD). This initiative aims to foster collaborative research through specialized centers supported by multi-project grant awards under the P50 activity code. The anticipated funding amount for each center is up to $1 million, with the NOFO expected to be published in Summer 2024 and applications due in Fall 2024. Interested applicants should prepare to develop meaningful collaborations and responsive projects, as the estimated award date is set for July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Deriving Common Data Elements from Real-World Data for Alzheimer�s Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at developing Common Data Elements (CDEs) for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) utilizing Real-World Data (RWD) from electronic health records and CMS claims. The objective is to enhance data harmonization and interoperability among disparate RWD systems, thereby facilitating more efficient research and faster production of real-world evidence. This funding opportunity, categorized as a cooperative agreement, has an estimated total program funding of $4 million, with a maximum award ceiling of $2.5 million, and is expected to result in one award. Interested applicants should prepare for the anticipated application due date in June 2024, following the expected publication of the NOFO in March 2024.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative aims to provide statistical expertise for the design, conduct, and data management of multi-center clinical trials, particularly focusing on late-phase treatment trials across various cancer types and patient demographics. The funding, estimated at $47 million, will support approximately five awards, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, interested applicants should prepare their proposals in advance of the anticipated timeline.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT), aimed at advancing research on Temporomandibular Disorders (TMD). This initiative seeks to establish a national, interdisciplinary collaborative that will enhance TMD research, improve clinical care, and train future researchers in the field. The funding opportunity will provide a total of $7 million, with an award ceiling of $3.5 million for up to two cooperative agreements, and is expected to be published in Summer 2024, with applications due in Winter 2024. Interested applicants should prepare for the anticipated collaboration and project development in advance of the expected award date of July 1, 2025.